Back to School: How biopharma can reboot drug development. Access exclusive analysis here

VBL begins Phase III of gene therapy VB-111 to treat ovarian cancer

Vascular Biogenics Ltd. (NASDAQ:VBLT) began the Phase III OVAL trial of ofranergene obadenovec (VB-111) to treat recurrent platinum-resistant ovarian cancer.

The U.S.

Read the full 220 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE